

Erratum to: Inhibition of BRCT(BRCA1)-phosphoprotein interaction enhances the cytotoxic effect of olaparib in breast cancer cells: a proof of concept study for synthetic lethal therapeutic option

Ziyan Yuan Pessetto¹ · Ying Yan¹ · Tadayoshi Bessho¹ · Amarnath Natarajan^{1,2,3}

Published online: 16 February 2016
© Springer Science+Business Media New York 2016

Erratum to: Breast Cancer Res Treat (2012)
134:511–517
DOI 10.1007/s10549-012-2079-4

Figure 1c in the original publication had nuclear lamin B B controls inserted in both the cytoplasm and nucleus sets. The revised Fig. 1c show the correct GAPDH controls. The authors regret this error.




Fig. 1 a Proposed hypothesis: Small molecule inhibitors of BRCT(BRCA1)–phosphoprotein interaction will increase the sensitivity of cancer cells to DNA damage based therapeutics. The inhibitor is represented as a *red X*. **b** Competitive inhibition curves for BRCT(BRCA1) inhibitor peptides **1** (Ac-pSPTF-CO₂H) and **2** (Ac-R10 G-pSPTF-CO₂H). **c** IP and IB studies with and without the BRCT inhibitor **2** in the presence and absence of IR-induced DNA damage

The online version of the original article can be found under doi:10.1007/s10549-012-2079-4.

✉ Amarnath Natarajan
anatarajan@unmc.edu

Ziyan Yuan Pessetto
zyuan@kumc.edu

- ¹ Eppley Institute for Cancer Research, University of Nebraska Medical Center, Omaha, NE 68198, USA
- ² Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE 68198, USA
- ³ Department of Genetics Cell Biology and Anatomy, University of Nebraska Medical Center, Omaha, NE 68198, USA